Hopkinton, Massachusetts-based Isto Biologics, a company focused on bone regeneration and cell therapy solutions, has acquired Los Angeles, California-based TheraCell, Inc., a regenerative medicine company.
Isto Biologics Acquires TheraCell
1 min read Premium comments
Secondary#istobiologics#theracell#therafuzedbf
Founded in 2008, TheraCell creates technologies for the repair of bone and soft tissue. In addition to its California-based headquarters, the company also has offices and laboratories in Littleton, Massachusetts.
TheraCell’s product portfolio incorporates its proprietary TheraFuze DBF® technology, an osteoconductive, 100% natural allograft. According to the press release, the TheraFuze DBF technology will be added to the Isto Biologics Influx™ line. Influx, per the Isto Biologics website, is an “advanced allograft technology that delivers regenerative capacity in a versatile 100% pure human bone graft.”
TheraCell’s product portfolio includes, per its website, “demineralized bone fiber” implants. The Fiber Anchor™ is an implant for screw augmentation. The Fiber Bag™ is an implant for graft containment.
Isto Biologics creates solutions for spine, orthopedics, and sports medicine procedures. Company CEO Don Brown expressed excitement about the acquisition. Brown stated, “We are thrilled to add TheraCell’s unmatched technology to our market-leading biologics portfolio.”
Brown continued, “TheraCell has excelled in developing advanced bone integrating, anchoring, and bridging technologies for spinal repair for over a decade including their award-winning TheraFuze DBF® Fiber Anchor™ and TheraFuze DBF® Fiber Bag™.”
TheraCell’s other products include the following: Fiber Bullets™, FiberWrap™, FiberBoat™, FiberForm™, FiberForm™+, FiberForm™ S, and FiberForm™+ S. These products are all demineralized bone fibers. The products with the “+” include mineralized cortical chips.
TheraCell’s Co-Founder and CEO Bradley Patt, Ph.D. commented, “We are pleased that Isto, a leader in allogeneic spine solutions, has recognized the value and importance of what we have developed and are excited about how their patient-centric, outcomes-focused commercial and clinical teams will rapidly accelerate the surgical adoption of the products and technology that we’ve always been passionate about.”
The terms of the deal were not disclosed.
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.